ANRO — Alto Neuroscience, Inc.

Alto Neuroscience, Inc. (ANRO) is a biotechnology company listed on NYSE. It is led by Amit Etkin M.D., Ph.D., based in 650 Castro Street, Mountain View, CA, United States, 94041, with about 76 employees. Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.

Net income was -$14.2M. ANRO currently screens at market cap $60.1M.

Use this ANRO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ANRO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ANRO SEC filings page. Lician reads the product cache first so this HTML stays unique to Alto Neuroscience, Inc. even when a live quote feed is slow.